136 related articles for article (PubMed ID: 35836271)
1. Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progression.
Ruchalski K; Kim HJ; Douek M; Raman S; Patel M; Sai V; Gutierrez A; Levine B; Fischer C; Allen-Auerbach M; Gupta P; Coy H; Villegas B; Brown M; Goldin J
Cancer Imaging; 2022 Jul; 22(1):34. PubMed ID: 35836271
[TBL] [Abstract][Full Text] [Related]
2. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
[TBL] [Abstract][Full Text] [Related]
3. In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.
Whitney CA; Howard LE; Posadas EM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
Eur Urol Focus; 2017 Oct; 3(4-5):480-486. PubMed ID: 28753787
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
[TBL] [Abstract][Full Text] [Related]
5. Abiraterone acetate treatment in patients with castration-resistant prostate cancer with visceral metastases: a real-world experience.
Facchini G; Cavaliere C; D'Aniello C; Iovane G; Rossetti S
Anticancer Drugs; 2019 Feb; 30(2):179-185. PubMed ID: 30320608
[TBL] [Abstract][Full Text] [Related]
6. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.
Evans CP; Higano CS; Keane T; Andriole G; Saad F; Iversen P; Miller K; Kim CS; Kimura G; Armstrong AJ; Sternberg CN; Loriot Y; de Bono J; Noonberg SB; Mansbach H; Bhattacharya S; Perabo F; Beer TM; Tombal B
Eur Urol; 2016 Oct; 70(4):675-683. PubMed ID: 27006332
[TBL] [Abstract][Full Text] [Related]
7. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019
[TBL] [Abstract][Full Text] [Related]
8. Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting.
Sayegh N; Tripathi N; Nussenzveig RH; Thomas VM; Tandar C; Goel D; Nordblad B; Sahu KK; Li H; L Maughan B; Agarwal N; Swami U
Eur Urol Focus; 2023 Jan; 9(1):106-109. PubMed ID: 35835693
[TBL] [Abstract][Full Text] [Related]
9. Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.
Loriot Y; Fizazi K; de Bono JS; Forer D; Hirmand M; Scher HI
Cancer; 2017 Jan; 123(2):253-262. PubMed ID: 27648814
[TBL] [Abstract][Full Text] [Related]
10. Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.
Boegemann M; Khaksar S; Bera G; Birtle A; Dopchie C; Dourthe LM; Everaert E; Hatzinger M; Hercher D; Hilgers W; Matus G; Alvarez LG; Antoni L; Lukac M; Pissart G; Robinson P; Elliott T
BMC Cancer; 2019 Jan; 19(1):60. PubMed ID: 30642291
[TBL] [Abstract][Full Text] [Related]
11. Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.
McNamara MA; Oyekunle T; Chin BB; Oldan J; Anand A; Ritz M; Shantzer L; Anand M; Armstrong AJ; George DJ
Prostate; 2019 Jul; 79(10):1106-1116. PubMed ID: 31045266
[TBL] [Abstract][Full Text] [Related]
12. Combined
Suman S; Parghane RV; Joshi A; Prabhash K; Talole S; Basu S
Prostate; 2021 Nov; 81(15):1225-1234. PubMed ID: 34469602
[TBL] [Abstract][Full Text] [Related]
13. Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis.
Alamiri J; Britton CJ; Ahmed ME; Andrews JR; Higa JL; Dundar A; Karnes RJ; Kwon E; Lowe VJ; Kendi AT; Bold MS; Pagliaro LC
Prostate; 2022 Dec; 82(16):1483-1490. PubMed ID: 36089822
[TBL] [Abstract][Full Text] [Related]
14. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.
Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo Perez JM; Wagner V; Li R; Nordquist LT
Ann Oncol; 2017 Oct; 28(10):2464-2471. PubMed ID: 28961839
[TBL] [Abstract][Full Text] [Related]
15. Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry.
Chowdhury S; Bjartell A; Lumen N; Maroto P; Paiss T; Gomez-Veiga F; Birtle A; Kramer G; Kalinka E; Spaëth D; Feyerabend S; Matveev V; Lefresne F; Lukac M; Wapenaar R; Costa L
Target Oncol; 2020 Jun; 15(3):301-315. PubMed ID: 32500294
[TBL] [Abstract][Full Text] [Related]
16. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer.
Pond GR; Sonpavde G; de Wit R; Eisenberger MA; Tannock IF; Armstrong AJ
Eur Urol; 2014 Jan; 65(1):3-6. PubMed ID: 24120464
[TBL] [Abstract][Full Text] [Related]
17. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Meyrick D; Gallyamov M; Sabarimurugan S; Falzone N; Lenzo N
Target Oncol; 2021 May; 16(3):369-380. PubMed ID: 33687624
[TBL] [Abstract][Full Text] [Related]
18. Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302.
Teply BA; Qiu F; Antonarakis ES; Carducci MA; Denmeade SR
Prostate; 2019 Jun; 79(8):929-933. PubMed ID: 31059588
[TBL] [Abstract][Full Text] [Related]
19. Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy.
Francini E; Montagnani F; Nuzzo PV; Gonzalez-Velez M; Alimohamed NS; Rosellini P; Moreno-Candilejo I; Cigliola A; Rubio-Perez J; Crivelli F; Shaw GK; Zhang L; Petrioli R; Bengala C; Francini G; Garcia-Foncillas J; Sweeney CJ; Higano CS; Bryce AH; Harshman LC; Lee-Ying R; Heng DYC
JAMA Netw Open; 2021 Jul; 4(7):e2116536. PubMed ID: 34292336
[TBL] [Abstract][Full Text] [Related]
20. Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer.
Parker SJ; Pond GR; Agarwal N; Alex A; Heilbrun ME; Sonpavde G
Clin Genitourin Cancer; 2017 Feb; 15(1):53-59. PubMed ID: 27338517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
